8 slides from Scancell's shareholder meeting presentation, Nov 6, 2012
Slide 1: AGM Presentation: Clinical Stage DNA Cancer Vaccines
AIM-listed clinical stage biotech company AGM Presentation Clinical Stage DNA Cancer Vaccines November 6th 2012
Slide 2: Disclaimer
Disclaimer These presentation materials have been prepared by and are the sole responsibility of the directors of Scancell Holdings plc. These presentation materials do not constitute or form part of any offer for sale or subscription or any solicitation for any offer to buy or subscribe for any sec
Slide 3: Highlights
Highlights Scancell has two flexible platforms for developing novel therapeutic cancer vaccines • ImmunoBody® (DNA vaccines) • Moditope™ (peptide vaccines) Phase 1/2 Clinical PoC data on ImmunoBody® being generated by SCIB1 • Part 1 data by YE2012 • Part 2 data by YE2013 (12 (11 evaluable)/13 patien
Slide 4: The potential of therapeutic cancer vaccines
The potential of therapeutic cancer vaccines Powerful immune response targeted to cancer cells Avoidance of normal cells may result in benign side effect profile Disease stabilisation, control and potential cure Survival benefit Turning cancer into a long term chronic disease 3
Slide 5: Cancer vaccine newsflow
Cancer vaccine newsflow Significant near-term newsflow expected Product Indication Phase Event Timing Allovectin (Vical) Stage 3 or Stage 4 Melanoma Phase III Topline results for primary Late 2012/Early 2013 (response rate) and secondary (OS) endpoints Lucanix (NovaRx Advanced Non-small Cell Lung Ph
Slide 6: What is ImmunoBody platform
What is ImmunoBody® platform Key advantages of ImmunoBody® Technology: Generate potent T cell responses that kill tumour cells, inhibit the growth of solid tumours and prevent the spread of metastatic disease Low cost, rapid and easy generic manufacturing process Platform can deliver multiple drugs
Slide 7: SCIB1 (DNA vaccine for Melanoma)
SCIB1 (DNA vaccine for Melanoma) • Induces powerful anti-tumour NH2 NH2 activity in vivo • CTA May 2010 • Phase 1/2 Clinical Trial started COOH June 2010 KEY: • Part 1 results 4Q12 gp100 DR4 epitope (L1 and H3) gp100 DR7,Dr53,DQ6 epitope (L3 and H1) • Part 2 started 2Q12 TRP-2 epitope (H2) COOH • Pa
Slide 8: Phase 1/2 trial in stage III/IV melanoma
Phase 1/2 trial in stage III/IV melanoma Primary Objective: To demonstrate safety and tolerability Secondary Objective: To demonstrate cellular immune response (high avidity T-cells) and tumour response Part One • 9 patients • 3 subjects per cohort; 0.4mg, 2.0 mg or 4.0 mg • Progression only if adeq